blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3003315

EP3003315 - A QUINOLINE INHIBITOR OF THE MACROPHAGE STIMULATING 1 RECEPTOR MST1R [Right-click to bookmark this link]
Former [2016/15]A QUINOLINE INHIBITOR OF THE MACROPHAGE STIMULATING 1 RECEPTOR MST1 R
[2017/27]
StatusNo opposition filed within time limit
Status updated on  23.11.2018
Database last updated on 12.07.2024
FormerThe patent has been granted
Status updated on  15.12.2017
FormerGrant of patent is intended
Status updated on  04.07.2017
FormerExamination is in progress
Status updated on  13.01.2017
Most recent event   Tooltip26.06.2020Lapse of the patent in a contracting state
New state(s): MK		published on 29.07.2020  [2020/31]
Applicant(s)For all designated states
Lead Discovery Center GmbH
Otto-Hahn-Strasse 15
44227 Dortmund / DE
[2018/03]
Former [2016/15]For all designated states
Merck Patent GmbH
Frankfurter Strasse 250
64293 Darmstadt / DE
Inventor(s)01 / SCHADT, Oliver
Forststrasse 4
63517 Rodenbach / DE
02 / ESDAR, Christina
Albanusstrasse 82a
55128 Mainz / DE
03 / SCHULTZ-FADEMRECHT, Carsten
Hollandstrasse 77 c
44309 Dortmund / DE
04 / EICKHOFF, Jan
Siepen 35
58313 Herdecke / DE
 [2018/03]
Former [2016/15]01 / SCHADT, Oliver
Forststrasse 4
63517 Rodenbach / DE
02 / ESDAR, Christina
Albanusstrasse 82a
55128 Mainz / DE
03 / SCHULTZ-FADEMRECHT, Carsten
Scherrweg 37
44309 Dortmund / DE
04 / EICKHOFF, Jan
Am Zickenkamp 6
58313 Heerdecke / DE
Representative(s)Arth, Hans-Lothar
ABK Patent Attorneys
Jasminweg 9
14052 Berlin / DE
[2018/03]
Application number, filing date14722116.207.05.2014
[2016/15]
WO2014EP01231
Priority number, dateEP2013000292606.06.2013         Original published format: EP 13002926
[2016/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014194975
Date:11.12.2014
Language:EN
[2014/50]
Type: A1 Application with search report 
No.:EP3003315
Date:13.04.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 11.12.2014 takes the place of the publication of the European patent application.
[2016/15]
Type: B1 Patent specification 
No.:EP3003315
Date:17.01.2018
Language:EN
[2018/03]
Search report(s)International search report - published on:EP11.12.2014
ClassificationIPC:A61K31/506, A61K31/4709, A61K45/06, A61P35/00, A61P31/00, A61P29/00, A61P27/06, A61P25/28, A61P19/02, A61P17/06, A61P15/00, A61P9/10, C07D401/14
[2017/27]
CPC:
C07D401/14 (EP,US); A61K31/4709 (EP,US); A61K31/506 (EP,US);
A61K45/06 (US); A61P15/00 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P25/28 (EP); A61P27/02 (EP);
A61P27/06 (EP); A61P29/00 (EP); A61P31/00 (EP);
A61P31/04 (EP); A61P35/00 (EP); A61P43/00 (EP);
A61P9/10 (EP) (-)
C-Set:
A61K31/4709, A61K2300/00 (US,EP);
A61K31/506, A61K2300/00 (EP,US)
Former IPC [2016/15]A61K31/506, A61K31/4709, A61K45/06, A61P35/00, A61P31/00, A61P29/00, A61P27/06, A61P25/28, A61P19/02, A61P17/06, A61P15/00, A61P9/10
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/15]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:CHINOLIN-DERIVAT ALS INHIBITOR VOM MAKROPHAGEN STIMMULIERENDEN 1 REZEPTOR MST1R[2017/27]
English:A QUINOLINE INHIBITOR OF THE MACROPHAGE STIMULATING 1 RECEPTOR MST1R[2017/27]
French:DÉRIVÉ DE QUINOLINE EN TANT QU'INHIBITEURS DE RÉCEPTEUR DE STIMULATION DE MACROPHAGES 1[2017/27]
Former [2016/15]CHINOLININHIBITOR DES MAKROPHAGENSTIMULIERENDEN 1-REZEPTORS MST1-R
Former [2016/15]A QUINOLINE INHIBITOR OF THE MACROPHAGE STIMULATING 1 RECEPTOR MST1 R
Former [2016/15]INHIBITEUR QUINOLÉIQUE DU RÉCEPTEUR D'ORIGINE NANTAISE MST1R
Entry into regional phase26.10.2015National basic fee paid 
26.10.2015Designation fee(s) paid 
26.10.2015Examination fee paid 
Examination procedure26.10.2015Examination requested  [2016/15]
14.04.2016Amendment by applicant (claims and/or description)
13.01.2017Despatch of a communication from the examining division (Time limit: M04)
07.03.2017Reply to a communication from the examining division
05.07.2017Communication of intention to grant the patent
01.11.2017Fee for grant paid
01.11.2017Fee for publishing/printing paid
06.11.2017Receipt of the translation of the claim(s)
Opposition(s)18.10.2018No opposition filed within time limit [2018/52]
Fees paidRenewal fee
10.05.2016Renewal fee patent year 03
10.05.2017Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.05.2014
AL17.01.2018
AT17.01.2018
CY17.01.2018
CZ17.01.2018
EE17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
MC17.01.2018
MK17.01.2018
PL17.01.2018
PT17.01.2018
RO17.01.2018
RS17.01.2018
SI17.01.2018
SK17.01.2018
SM17.01.2018
BG17.04.2018
GR18.04.2018
IE07.05.2018
LU07.05.2018
MT07.05.2018
IS17.05.2018
[2020/31]
Former [2020/30]HU07.05.2014
AL17.01.2018
AT17.01.2018
CY17.01.2018
CZ17.01.2018
EE17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
MC17.01.2018
PL17.01.2018
PT17.01.2018
RO17.01.2018
RS17.01.2018
SI17.01.2018
SK17.01.2018
SM17.01.2018
BG17.04.2018
GR18.04.2018
IE07.05.2018
LU07.05.2018
MT07.05.2018
IS17.05.2018
Former [2020/28]AL17.01.2018
AT17.01.2018
CY17.01.2018
CZ17.01.2018
EE17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
MC17.01.2018
PL17.01.2018
PT17.01.2018
RO17.01.2018
RS17.01.2018
SI17.01.2018
SK17.01.2018
SM17.01.2018
BG17.04.2018
GR18.04.2018
IE07.05.2018
LU07.05.2018
MT07.05.2018
IS17.05.2018
Former [2020/08]AL17.01.2018
AT17.01.2018
CY17.01.2018
CZ17.01.2018
EE17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
MC17.01.2018
PL17.01.2018
RO17.01.2018
RS17.01.2018
SI17.01.2018
SK17.01.2018
SM17.01.2018
BG17.04.2018
GR18.04.2018
IE07.05.2018
LU07.05.2018
MT07.05.2018
IS17.05.2018
Former [2019/19]AL17.01.2018
AT17.01.2018
CY17.01.2018
CZ17.01.2018
EE17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
MC17.01.2018
PL17.01.2018
RO17.01.2018
RS17.01.2018
SI17.01.2018
SK17.01.2018
SM17.01.2018
BG17.04.2018
GR18.04.2018
IE07.05.2018
LU07.05.2018
IS17.05.2018
Former [2019/17]AL17.01.2018
AT17.01.2018
CY17.01.2018
CZ17.01.2018
EE17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
MC17.01.2018
PL17.01.2018
RO17.01.2018
RS17.01.2018
SI17.01.2018
SK17.01.2018
SM17.01.2018
BG17.04.2018
GR18.04.2018
LU07.05.2018
IS17.05.2018
Former [2019/13]AL17.01.2018
AT17.01.2018
CY17.01.2018
CZ17.01.2018
EE17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
MC17.01.2018
PL17.01.2018
RO17.01.2018
RS17.01.2018
SI17.01.2018
SK17.01.2018
SM17.01.2018
BG17.04.2018
GR18.04.2018
IS17.05.2018
Former [2019/06]AL17.01.2018
AT17.01.2018
CY17.01.2018
CZ17.01.2018
EE17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
MC17.01.2018
PL17.01.2018
RO17.01.2018
RS17.01.2018
SK17.01.2018
SM17.01.2018
BG17.04.2018
GR18.04.2018
IS17.05.2018
Former [2018/52]AL17.01.2018
AT17.01.2018
CY17.01.2018
CZ17.01.2018
EE17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
PL17.01.2018
RO17.01.2018
RS17.01.2018
SK17.01.2018
SM17.01.2018
BG17.04.2018
GR18.04.2018
IS17.05.2018
Former [2018/50]AL17.01.2018
AT17.01.2018
CY17.01.2018
CZ17.01.2018
EE17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
PL17.01.2018
RO17.01.2018
RS17.01.2018
SK17.01.2018
BG17.04.2018
GR18.04.2018
IS17.05.2018
Former [2018/49]AL17.01.2018
AT17.01.2018
CY17.01.2018
EE17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
PL17.01.2018
RO17.01.2018
RS17.01.2018
BG17.04.2018
GR18.04.2018
IS17.05.2018
Former [2018/46]AL17.01.2018
AT17.01.2018
CY17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
PL17.01.2018
RS17.01.2018
BG17.04.2018
GR18.04.2018
IS17.05.2018
Former [2018/40]AT17.01.2018
CY17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
PL17.01.2018
RS17.01.2018
BG17.04.2018
GR18.04.2018
IS17.05.2018
Former [2018/39]AT17.01.2018
CY17.01.2018
HR17.01.2018
LT17.01.2018
LV17.01.2018
PL17.01.2018
RS17.01.2018
GR18.04.2018
IS17.05.2018
Former [2018/37]CY17.01.2018
HR17.01.2018
LT17.01.2018
PL17.01.2018
GR18.04.2018
Former [2018/36]CY17.01.2018
HR17.01.2018
LT17.01.2018
PL17.01.2018
Former [2018/35]CY17.01.2018
HR17.01.2018
LT17.01.2018
Cited inInternational search[AD]WO2006116713  (AMGEN INC [US], et al) [AD] 1-6 * the whole document ** examples 1-239 *;
 [A]WO2007146824  (ARRAY BIOPHARMA INC [US], et al) [A] 1-6 * the whole document * * examples 1-106 *;
 [A]EP2423208  (LEAD DISCOVERY CENTER GMBH [DE], et al) [A] 1-6 * the whole document * * examples 1-87 *;
 [AD]  - TED UNDERINER ET AL, "Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates", ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, (20100101), vol. 10, no. 1, doi:10.2174/1871520611009010007, ISSN 1871-5206, pages 7 - 27, XP055136161 [AD] 1-6 * the whole document * * tables 12,13,17 *

DOI:   http://dx.doi.org/10.2174/1871520611009010007
 [AD]  - PORTER J, "Small molecule c-Met kinase inhibitors: A review of recent patents", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, (20100201), vol. 20, no. 2, ISSN 1354-3776, pages 159 - 177, XP009147272 [AD] 1-6 * the whole document *
 [AD]  - RAEPPEL S ET AL, "Identification of a novel series of potent RON receptor tyrosine kinase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 9, ISSN 0960-894X, (20100501), pages 2745 - 2749, (20100319), XP027012825 [AD] 1-6 * the whole document *
 [AD]  - LONGBIN LIU ET AL, "Discovery of a Potent, Selective, and Orally Bioavailable c-Met Inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (20080701), vol. 51, doi:10.1021/JM800401T, ISSN 0022-2623, pages 3688 - 3691, XP008140337 [AD] 1-6 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm800401t
by applicantUS6069134
 WO0050032
 WO2006116713
    - WEINSTEIN-OPPENHEIMER ET AL., PHARMA. &. THERAP., (2000), vol. 88, pages 229 - 279
    - BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2010), vol. 20, pages 2745 - 2749
    - J.M. O'TOOLE ET AL., CANCER RES., (2006), vol. 66, page 9162
    - P.C. MA; G. MAULIK; J. CHRISTENSEN; R. SALGIA, CANCER METASTASIS REV, (2003), vol. 22, page 309
    - C.W. BIRCHMEIER; W. BIRCHMEIER; E. GHERARDI; G.F. VANDE WOUDE, NAT. REV. MOL. CELL BIOL., (2003), vol. 4, page 915
    - J.G. CHRISTENSEN; J. BURROWS; R. SALGIA, CANCER LETT, (2005), vol. 225, page 1
    - S. CORSO; P.M. COMOGLIO; S. GIORDANO, TRENDS MOL. MED., (2005), vol. 11, page 284
    - C. BOCCACCIO; P.M. COMOGLIO, NAT. REV. CANCER, (2006), vol. 6, page 637
    - B. PERUZZI; D.P. BOTTARO, CLIN. CANCER RES., (2006), vol. 12, page 3657
    - B.S. KNUDSEN; G. VANDE WOUDE, CUR. OPIN. GEN. DEV., (2008), vol. 18, page 87
    - L. TOSCHI; P.A. JANNE, CLIN. CANCER RES., (2008), vol. 14, page 5941
    - I. DUSSAULT; S.F. BELLON, ANTI-CANCER AGENTS MED. CHEM., (2009), vol. 9, page 221
    - N.A. CIPRIANI; 0.0. ABIDOYE; E. VOKES; R. SALGIA, LUNG CANCER, (2009), vol. 63, page 169
    - J. PORTER, EXPERT OPIN. THER. PATENTS, (2010), vol. 20, page 159
    - T.L. UNDERINER; T. HERBERTZ; S.J. MIKNYOCZKI, ANTI-CANCER AGENTS MED. CHEM., (2010), vol. 10, page 7
    - J.ZHANG ET AL., CANCER RES., (2008), vol. 68, page 6680
    - L.LIU ET AL., J. MED. CHEM., (2008), vol. 51, page 3688
    - G.M. SCHROEDER ET AL., J. MED. CHEM., (2009), vol. 52, page 1251
    - INT. J. PHARM., (1995), vol. 115, pages 61 - 67
    - KHWAJA ET AL., EMBO, (1997), vol. 16, pages 2783 - 93
    - WHITE ET AL., ONCOGENE, (2001), vol. 20, pages 7064 - 7072
    - STEPHENS ET AL., BIOCHEMICAL J., (2000), vol. 351, pages 95 - 105
    - ALESSI ET AL., FEBS LETT, (1996), vol. 399, no. 3, pages 333 - 338
    - CAMPOS-GONZAIEZ, R.; GLENNEY, JR., J.R, J. BIOL. CHEM., (1992), vol. 267, page 14535
    - SORG ET AL., J. OF. BIOMOLECULAR SCREENING, (2002), vol. 7, pages 11 - 19
    - SILLS ET AL., J. OF BIOMOLECULAR SCREENING, (2002), pages 191 - 214
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.